Christopher K Lippincott
Overview
Explore the profile of Christopher K Lippincott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishnan S, Rivera M, Lippincott C, Shah M
AIDS Res Ther
. 2025 Mar;
22(1):27.
PMID: 40025526
Introduction: Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e. pregnancy) often necessitate individualized antiretroviral therapy (ART) regimens. This study aimed to...
2.
Rimal B, Lippincott C, Panthi C, Xie Y, Keepers T, Alley M, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0064824.
PMID: 39016592
( or ) is a fast-growing mycobacterium that is ubiquitous in the environment and can cause opportunistic disease in people with lung comorbidity and immunodeficiency. There are no Food and...
3.
Ignatius E, Rimal B, Panthi C, Belz D, Lippincott C, Deck D, et al.
mSphere
. 2024 Jul;
9(7):e0038124.
PMID: 38980071
Treatment outcomes for (, also known as ) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating disease is challenging due to its high...
4.
Lippincott C, Lamichhane G
Antimicrob Agents Chemother
. 2024 Jun;
68(7):e0058524.
PMID: 38837394
Individuals with compromised lung function and immunity are susceptible to developing chronic infection. Current treatment recommendations typically involve using one β-lactam antibiotic in combination with non-β-lactam antibiotics. However, a recent...
5.
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease
Rimal B, Panthi C, Xie Y, Belz D, Ignatius E, Lippincott C, et al.
Tuberculosis (Edinb)
. 2024 Feb;
146:102482.
PMID: 38364332
Mycobacteroides abscessus (Mab, also known as Mycobacterium abscessus) causes opportunistic pulmonary and soft tissue infections that are difficult to cure with existing treatments. Omadacycline, a new tetracycline antibiotic, exhibits potent...
6.
Krishnan S, Lippincott C, Bjerrum S, Rivera M, Shah M
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad541.
PMID: 38023561
Background: HIV clinical practice guidelines outline broad treatment principles but offer less explicit recommendations by permutations of encountered viral resistance. We hypothesize that there is variability in antiretroviral (ARV) regimen...
7.
Rimal B, Nicklas D, Panthi C, Lippincott C, Belz D, Ignatius E, et al.
mSphere
. 2023 Mar;
8(2):e0066522.
PMID: 36912629
Mycobacteroides abscessus is an opportunistic pathogen in people with structural lung conditions such as bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis. Pulmonary M. abscessus infection causes progressive symptomatic and...
8.
Lippincott C, Perry A, Munk E, Maltas G, Shah M
BMC Infect Dis
. 2022 Oct;
22(1):800.
PMID: 36289485
Background: In-person directly observed therapy (DOT) is commonly used for tuberculosis (TB) treatment monitoring in the US, with increasing usage of video-DOT (vDOT). We evaluated the impact of COVID-19 on...
9.
Do Vale C, Naicker S, Lippincott C
Kidney Int Rep
. 2022 May;
7(4):920-923.
PMID: 35497785
No abstract available.
10.
Sadler E, Avdic E, Cosgrove S, Hohl D, Grimes M, Swarthout M, et al.
Am J Health Syst Pharm
. 2021 May;
78(13):1223-1232.
PMID: 33944904
Purpose: To identify barriers to safe and effective completion of outpatient parenteral antimicrobial therapy (OPAT) in patients discharged from an academic medical center and to develop targeted solutions to potentially...